PTCT stock drops on setback for mid-stage Huntington's disease trial (NASDAQ:PTCT)
seekingalpha.com
finance
2022-10-19 11:18:45

Hailshadow PTC Therapeutics (NASDAQ:PTCT), a biotech focused on rare disorders, fell ~14% pre-market Wednesday after the company said it paused enrollment in Phase 2 PIVOT-HD trial for Huntington's disease candidate PTC518 in the U.S. The decision follows a request made by the FDA seeking additional data to permit the study to advance in the U.S., PTCT said, adding that the findings from the global trial indicated no treatment-related adverse events so far. The study, designed to evaluate two dose levels, 5 milligrams and 10 milligrams of PTC518, with the potential to test a third dose level, started initially in the U.
